Elanco Animal Health faces securities fraud lawsuit amid FDA treatment delays

USA – Elanco Animal Health Incorporated is facing a securities fraud lawsuit following setbacks in the approval process for two of its critical new treatments by the U.S. Food and Drug Administration (FDA). 

The lawsuit, spearheaded by law firm Bleichmar Fonti & Auld (BFA Law), alleges that the company and its top executives violated federal securities laws by providing misleading information to investors.

At the center of the legal dispute are two products under FDA review: Zenrelia, a once-daily oral medication for treating canine dermatitis, and Credelio Quattro, a broad-spectrum parasiticide that targets fleas, ticks, and internal parasites. 

Initially, Elanco assured investors that both treatments were on track for FDA approval by the end of June 2024, stating that all necessary data had been submitted and approvals, including final labeling, were imminent.

However, on June 27, 2024, Elanco announced an unexpected delay. The FDA raised concerns regarding the safety of Zenrelia, stating that it would require a boxed safety warning, a significant blow that was not anticipated by investors.

As a result, the company’s stock tumbled, plummeting 21% from US$17.97 to US$14.27 per share.

The lawsuit, titled Barpar v. Elanco Animal Health Incorporated, et al., is currently being heard in the U.S. District Court for Maryland. 

BFA Law contends that Elanco misrepresented the likelihood of FDA approval for the treatments, creating a misleading picture of the company’s business and financial outlook. 

The firm is investigating whether Elanco failed to disclose critical information regarding the safety concerns with Zenrelia and the timeline for Credelio Quattro’s approval, which ultimately led to severe financial losses for shareholders.

Despite these legal challenges, Elanco has since received FDA approval for both treatments. Zenrelia was approved on September 19, 2024, and launched in the U.S. as a treatment for dogs suffering from allergic and atopic dermatitis. 

Credelio Quattro, a monthly chewable parasiticide, gained FDA approval on October 7, 2024, offering protection against six types of parasites, including fleas, ticks, and heartworms.

According to the lawsuit, the plaintiffs allege that during the Class Period, Elanco made misleading statements regarding the safety of Zenrelia and the likelihood of approval for both products. 

They argue that the company overstated its business prospects, leading to investor losses once the true situation was revealed.

Shareholders interested in participating in the class action must file their motions by December 6, 2024, if they wish to serve as the lead plaintiff. The lead plaintiff acts on behalf of all class members in directing the litigation. Those who opt out of active participation can still be eligible for any recovery if the lawsuit succeeds.

Amid the ongoing litigation, Elanco is set to announce its third-quarter 2024 financial results on November 7, 2024. The company will host a conference call that morning, providing further insights into its performance and addressing its future plans.

Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.